Synapse Open Synapse
Biology

CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial

BioPharma Dive · · 2 min read

CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares.

Latest from BioPharma Dive